Harrow Announces Participation in Annual Ophthalmology Conference
Harrow (Nasdaq: HROW), a prominent name in the North American eyecare pharmaceutical industry, has revealed that its management team will partake in the prestigious H.C. Wainwright's 5th Annual Ophthalmology Conference. This virtual event is an essential gathering for professionals in the ophthalmology field, enabling discussions about innovative treatments and advancements.
Key Engagements During the Conference
Mark L. Baum, Harrow's Chief Executive Officer, alongside Chief Financial Officer Andrew Boll, is set to engage in a fireside chat on the morning of the conference. This chat is scheduled for 8:30 a.m. Eastern time, allowing attendees valuable insights into Harrow's strategic vision and recent developments. Additionally, Baum will participate in a panel discussion centered on "Novel Treatments for Front-of-the-Eye Indications" later in the day at 1 p.m. Eastern time.
Webcast Availability
For those interested in following the proceedings of this significant event, both the fireside chat and panel discussion will be broadcast live via webcast, accessible through Harrow's official website. After the live session, a replay will be available for around 90 days, ensuring that even those who miss the live event can catch up on the important discussions.
Understanding Harrow's Mission and Vision
Harrow, Inc. (Nasdaq: HROW) is dedicated to the discovery, development, and commercialization of pioneering ophthalmic pharmaceutical products. The company’s mission extends beyond just providing medications; it aims to ensure that healthcare professionals can easily access affordable solutions to protect and preserve sight for millions of patients each year.
Impact on Eyecare Professionals
With an innovative portfolio, Harrow emphasizes the importance of making ophthalmic products both accessible and affordable. This commitment resonates throughout the eyecare community as professionals witness enhanced patient care through the solutions Harrow provides.
Company Contacts for Inquiries
For further questions about Harrow or its participation in the conference, interested parties can reach out to Mike Biega, the Vice President of Investor Relations and Communications. Mike is available via email at mbiega@harrowinc.com or by phone at 617-913-8890. Harrow encourages open communication to foster relationships with stakeholders and the community.
Frequently Asked Questions
What is the focus of Harrow at the conference?
Harrow will discuss its innovative ophthalmic pharmaceutical products and engage in discussions about novel treatments.
Who from Harrow is participating in the conference?
Mark L. Baum, CEO, and Andrew Boll, CFO, will represent Harrow during the session.
How can I access the webcast of the events?
The sessions will be available via live broadcast on Harrow’s official website, with recordings accessible for 90 days afterward.
What is Harrow's mission in eyecare?
Harrow’s mission is to provide innovative, accessible, and affordable eyecare products to help professionals preserve patient sight.
How can I get in contact with Harrow?
For inquiries, you can contact Mike Biega at mbiega@harrowinc.com or call 617-913-8890.
